Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2023 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The question asks if a substantial part of the forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies or serves, such that the company's own coming volume is a consequence of those parties' trajectories. Looking at the transcript, management discusses their own growth, product launches, acquisitions, and market conditions. They mention "we believe the elective surgery markets we serve remain healthy with higher than normal procedural demand" and "we expect that trend will persist through 2024 and likely 2025 as pandemic-related patient backlogs are gradually worked down." That's about market demand, not specific counterparties' own ramps. They talk about their own innovation pipeline, share gains, and EGX productivity. They mention "good initial traction for our industry-leading AltiVate and EMPOWR products" but that's about their own products. They discuss the Lima acquisition and integration, but that's about a company they are acquiring, not a counterparty they supply. They talk about "MotionMD clinic conversions" but that's a channel, not a specific counterparty's expansion. They mention "strong customer service" and "share gains" but not narrating a specific customer's build-out. The question requires that management speaks about identifiable counterparties' own trajectories as the driver. Here, management speaks about broad market trends, their own product launches, and acquisitions. They do not describe a specific customer or partner's expansion plans as the reason for their own growth. They mention "we have a strong pipeline of innovation" and "we continue to take share" which is their own effort. They also mention "we are seeing consistent performance in both of our business segments" but that's not about counterparties. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.